Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen

Lipi Chakravorty, Anthea Gibbons, Nirija Anderson, Fiona Kwok, Dariusz Korczyk, Emad Uddin Abro, Stephanie Lam, Simon Gibbs, Peter Mollee, M Hasib Sidiqi

Blood (2023) 142 (Supplement 1): 4781.

https://doi.org/10.1182/blood-2023-186335

Published: 2023

Journal Articles

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Blood (2023) 142 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2023-185169

Published: 2023

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Costas K. Yannakou, Nicholas Murphy, Rosemary Anne Harrup, Craig Wallington-Gates, Magdalena Sobieraj-Teague, M Hasib Sidiqi, Anish Puliyayil, Wojt Janowski, John Reynolds, Andrew Spencer, Hang Quach

Blood (2023) 142 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2023-185944

Published: 2023

Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Blood (2023) 142 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2023-178778

Published: 2023

Journal Articles

Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

Abdullah S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Harsh Parmar, MD, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Prashant Kapoor, MD, Robert Wolf, PharmD, RPh, Angela Dispenzieri, MD, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-143125

Published: 2020

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Journal Articles

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Stephanie Clugston, MBBS (Hons), Portia Smallbone, MBBS, Duncan Purtill, MBBS,FRCPA,FRACP, Dustin Hall, MBBS,FRCPA,FRACP, Rebecca De Kraa, BSc, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141784

Published: 2020

Journal Articles

Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

Abdullah S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Harsh Parmar, MD, Alissa Visram, MD, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Prashant Kapoor, MD, Robert Wolf, PharmD, RPh, Angela Dispenzieri, MD, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143076

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Kalyan Nadiminti, M Hasib Sidiqi, MBBS, Kapil Meleveedu, MDMBBS, Hassan B. Alkhateeb, MD, Aref Al-Kali, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Shaji K. Kumar, MD, Mrinal M Patnaik, MDMBBS, Morie A. Gertz, MD, Dong Chen, MD PhD, Mithun Vinod Shah, MD PhD

Blood (2019) 134 (Supplement_1): 4560.

https://doi.org/10.1182/blood-2019-123065

Published: 2019

Journal Articles

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Abdullah S. Al Saleh, MBBS, M Hasib Sidiqi, MBBS, Morie A. Gertz, MD, Eli Muchtar, MD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Suzanne R. Hayman, MD, Prashant Kapoor, MD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, David Dingli, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 4505.

https://doi.org/10.1182/blood-2019-131380

Published: 2019

Journal Articles

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Adeela Mushtaq, MD, Hamza Hassan, MD MBBS, Razwana Khanam, MD, Ahmad Iftikhar, MD, Midhat Lakhani, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Seemal Iftikhar, MD, Aneeqa A Zafar, MD, Irbaz Riaz, MDMMSc, M Hasib Sidiqi, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5556.

https://doi.org/10.1182/blood-2019-125148

Published: 2019

Journal Articles

Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis

Abdullah S. Al Saleh, MBBS, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, Rahma M Warsame, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Nelson Leung, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Ronald S. Go, MD, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Morie A Gertz, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 5532.

https://doi.org/10.1182/blood-2019-131171

Published: 2019

Journal Articles

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant

M Hasib Sidiqi, MBBS, Abdullah S. S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, Eli Muchtar, MD, Rahma M Warsame, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Nelson Leung, MD, Wilson I Gonsalves, MD, Prashant Kapoor, MD, Taxiarchis Kourelis, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, Morie A Gertz, MD

Blood (2019) 134 (Supplement_1): 3171.

https://doi.org/10.1182/blood-2019-125453

Published: 2019

Journal Articles

Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma

Blood (2018) 132 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2018-99-114882

Published: 2018

Journal Articles

Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis

Blood (2018) 132 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2018-99-117627

Published: 2018

Journal Articles

Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival

M Hasib Sidiqi, MBBS, Mohammed A Aljama, MBBS, FRCPC, Angela Dispenzieri, MD, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, Rahma Warsame, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Nelson Leung, MD, Wilson I Gonsalves, MD, Prashant Kapoor, MD, Taxiarchis Kourelis, MD, William J. Hogan, MBBCh, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2018-99-113665

Published: 2018

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience

Blood (2018) 132 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2018-99-111147

Published: 2018

Journal Articles

T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders

M Hasib Sidiqi, MBBS, Mohammed A Aljama, MBBS,FRCPC, David S. Viswanatha, MD, David Dingli, MD PhD

Blood (2018) 132 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2018-99-114953

Published: 2018

NARROW

Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant

Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma

Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis

Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival

Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience

T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only